To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
showing 1-10 of 465
This factsheet provides answers to the most frequently asked questions about the Dual Prevention Pill (DPP), including what it is, who might use it, and how it can be rolled out.
AVAC tracks global PrEP use by conducting quarterly surveys of ongoing oral PrEP demonstration and implementation projects, and collecting data from manufacturers and government agencies. This graphic shows data on PrEP initiations around the globe....
TCA’s invited experts will share their highlights and reflections on the HIV and STI-related science presented at two major global health conferences.
In its 17th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2021. This report also analyzes funding trends spanning 22 years for the following biomedical HIV prevention options: preventive HIV vaccines, microbicides, PrEP, treatment as prevention, voluntary medical male circumcision, female condoms and prevention of vertical transmission.
The 2021 report of Cure Resource Tracking Group, a collaboration between AVAC and the International AIDS Society, showed a remarkable 30 percent increase in funding for cure research. The report also provides an analysis of the cure research agenda and the scientific questions shaping investment decisions.
Advocates Brian Minalga (Deputy Director of the Office of HIV/AIDS Network Coordination), Amir Sadeghi (Policy and Advocacy Manager at the The Center for HIV Law and Policy), and Andy Spieldenner (Executive Director of MPact Global Action) will explore the intersection of surveillance, bodily autonomy and criminalization.
Important progress has been made, but ending the AIDS epidemic will require a comprehensive approach that is evidence-informed, rights-based, person-centered and adequately resourced.
A snapshot of early phase trials testing mRNA-based HIV vaccines.
Most of what we hear about regarding the HIV prevention pipeline is about long-acting, longer-acting, and even longer-acting products that deliver drug throughout the body and require a trained clinician to deliver.
AVAC tracks PrEP initiations around the world. This infographic represents the cumulative number of PrEP initiations in Q1 2023.
showing 1-10 of 465